Literature DB >> 21367651

Fighting bacterial infections-future treatment options.

Jenny Fernebro1.   

Abstract

This review summarizes ongoing research aimed at finding novel drugs as alternatives to traditional antibiotics. Anti-virulence approaches, phage therapy and therapeutic antibodies are strategies that may yield drugs with high specificity and narrow spectra. Several candidates are currently being evaluated in clinical trials, mostly for topical applications, but so far, none have been approved for market authorization. Candidates based on antimicrobial peptides (natural, semisynthetic and synthetic) are also being tested in clinical trials, mostly for the topical treatment of chronic infections. An alternative to the development of new antibiotics is to find potentiators of traditional antibiotics; in this respect, beta-lactamase inhibitors are already in clinical use. Novel variants are under investigation as well as efflux pump inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367651     DOI: 10.1016/j.drup.2011.02.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  37 in total

1.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

Review 2.  Targeting virulence: can we make evolution-proof drugs?

Authors:  Richard C Allen; Roman Popat; Stephen P Diggle; Sam P Brown
Journal:  Nat Rev Microbiol       Date:  2014-04       Impact factor: 60.633

3.  Talactoferrin.

Authors:  Hilary Denis Solomons
Journal:  Germs       Date:  2012-09-01

4.  Co-evolution with lytic phage selects for the mucoid phenotype of Pseudomonas fluorescens SBW25.

Authors:  Pauline Deirdre Scanlan; Angus Buckling
Journal:  ISME J       Date:  2011-12-22       Impact factor: 10.302

5.  The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases.

Authors:  Thibaut Boibessot; Christopher P Zschiedrich; Alexandre Lebeau; David Bénimèlis; Catherine Dunyach-Rémy; Jean-Philippe Lavigne; Hendrik Szurmant; Zohra Benfodda; Patrick Meffre
Journal:  J Med Chem       Date:  2016-09-26       Impact factor: 7.446

6.  Gold Nanoparticles with Antibiotic-Metallopolymers toward Broad-Spectrum Antibacterial Effects.

Authors:  Peng Yang; Parasmani Pageni; Md Anisur Rahman; Marpe Bam; Tianyu Zhu; Yung Pin Chen; Mitzi Nagarkatti; Alan W Decho; Chuanbing Tang
Journal:  Adv Healthc Mater       Date:  2018-11-27       Impact factor: 9.933

7.  Phage Therapy Is Effective in a Mouse Model of Bacterial Equine Keratitis.

Authors:  Takaaki Furusawa; Hidetomo Iwano; Yutaro Hiyashimizu; Kazuki Matsubara; Hidetoshi Higuchi; Hajime Nagahata; Hidekazu Niwa; Yoshinari Katayama; Yuta Kinoshita; Katsuro Hagiwara; Tomohito Iwasaki; Yasunori Tanji; Hiroshi Yokota; Yutaka Tamura
Journal:  Appl Environ Microbiol       Date:  2016-08-15       Impact factor: 4.792

8.  Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa.

Authors:  Xin Zhu; Anshan Shan; Zhi Ma; Wei Xu; Jiajun Wang; Shuli Chou; Baojing Cheng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

9.  Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models.

Authors:  Steven Boakes; William J Weiss; Mary Vinson; Sjoerd Wadman; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

10.  [Not Available].

Authors:  R Le Floch; E Naux; J F Arnould
Journal:  Ann Burns Fire Disasters       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.